首页> 外文期刊>Journal of Personalized Medicine >Personalized Medicine in the U.S. and Germany: Awareness, Acceptance, Use and Preconditions for the Wide Implementation into the Medical Standard
【24h】

Personalized Medicine in the U.S. and Germany: Awareness, Acceptance, Use and Preconditions for the Wide Implementation into the Medical Standard

机译:美国和德国的个性化医学:广泛实施医学标准的认识,接受,使用和前提条件

获取原文
           

摘要

The aim of our research was to collect comprehensive data about the public and physician awareness, acceptance and use of Personalized Medicine (PM), as well as their opinions on PM reimbursement and genetic privacy protection in the U.S. and Germany. In order to give a better overview, we compared our survey results with the results from other studies and discussed Personalized Medicine preconditions for its wide implementation into the medical standard. For the data collection, using the same methodology, we performed several surveys in Pennsylvania (U.S.) and Bavaria (Germany). Physicians were contacted via letter, while public representatives in person. Survey results, analyzed by means of descriptive and non-parametric statistic methods, have shown that awareness, acceptance, use and opinions on PM aspects in Pennsylvania and Bavaria were not significantly different. In both states there were strong concerns about genetic privacy protection and no support of one genetic database. The costs for Personalized Medicine were expected to be covered by health insurances and governmental funds. Summarizing, we came to the conclusion that for PM wide implementation there will be need to adjust the healthcare reimbursement system, as well as adopt new laws which protect against genetic misuse and simultaneously enable voluntary data provision.
机译:我们研究的目的是收集有关公众和医师对个性化医学(PM)的认识,接受和使用的全面数据,以及他们在美国和德国对PM报销和遗传隐私保护的意见。为了提供更好的概述,我们将调查结果与其他研究的结果进行了比较,并讨论了个性化医学将其广泛应用于医学标准的前提条件。对于数据收集,使用相同的方法,我们在宾夕法尼亚州(美国)和巴伐利亚州(德国)进行了几次调查。通过信件与医师联系,而亲自与公众代表联系。通过描述性和非参数统计方法进行的调查结果表明,宾夕法尼亚州和巴伐利亚州对PM方面的认识,接受,使用和观点没有显着差异。在这两个州,人们对基因隐私的保护表示强烈关注,并且没有一个基因数据库的支持。个性化医学的费用预计将由健康保险和政府资金支付。总而言之,我们得出的结论是,要在广泛的PM范围内实施,就需要调整医疗保健报销系统,并采用新的法律来防止遗传滥用并同时能够自愿提供数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号